Jasper Therapeutics Secures $30 Million Equity Funding for Corporate Growth and Development Purposes Jasper Therapeutics, a biopharmaceutical company focused on […]
Rare Disease Diagnosis Leads to Life-Changing Treatment and Newfound Purpose for Young Man Walker Burger lived his entire childhood under
Evommune’s EVO756 Shows 93% Clinical Response in Phase 2 Chronic Urticaria Trial Results Evommune, a clinical-stage biotech company, has announced
Evommune’s EVO756 Shows 93% Clinical Response in Phase 2 Chronic Urticaria Trial Results Read Post »
Jasper Therapeutics Raises $30 Million Through Public Offering at $2.43 Per Share Jasper Therapeutics, a biopharmaceutical company focused on developing
Jasper Therapeutics Raises $30 Million Through Public Offering at $2.43 Per Share Read Post »
Jasper Therapeutics Raises $30 Million for Innovative Mast Cell Disease Treatments and Research Jasper Therapeutics, a biopharmaceutical company focused on
Understanding Pre-Diagnostic Systemic Mastocytosis Without Skin Symptoms and Its Implications Fully Mast cell diseases, including Pre-diagnostic Systemic Mastocytosis (PD-SM) and
Jasper Therapeutics’ Capital Raise: Shareholder Value at Risk of Significant Dilution Ahead Jasper Therapeutics, a biotechnology company focused on developing
Jasper Therapeutics’ Strategic Public Offering: Navigating a Challenging Biotech Landscape Successfully Today Jasper Therapeutics, a biopharmaceutical company focused on developing
Jasper Therapeutics Pursues Public Offering Amidst Promising Monoclonal Antibody Therapy Developments Jasper Therapeutics, a biopharmaceutical company focused on developing innovative
Jasper Therapeutics Pursues Public Offering to Fuel Preclinical and Clinical Development Programs Forward Jasper Therapeutics, a biotechnology company focused on
